Although a few clinical trials from Japan, such as combined androgen blockade for AR (Androgen receptor)-positive salivary gland cancer and trastuzumab, an anti-HER2 antibody, plus docetaxel therapy for HER2-positive SDCs, have brought favorable results (11, 16), there is no stratification currently available for personalized treatment selection and no consensus regarding a standard treatment or protocol. This evidence concerns the gene ERBB2 and salivary gland cancer.